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ABSTRACT
Therapy of infections caused by extended-spectrum b-lactamase (ESBL)-producing bacteria with an
antimicrobial to which they are resistant results in treatment failure, higher cost and increased mortality.
The CLSI recommends reporting ESBL-producing strains of Escherichia coli, Klebsiella spp. and Proteus
spp. as resistant to all penicillin, true cephalosporin and monobactam antimicrobials, but as susceptible
to b-lactam–b-lactamase inhibitor combinations, including piperacillin–tazobactam, when they test as
such. Current literature supports the action of piperacillin–tazobactam against susceptible strains of
ESBL-producing bacteria based on the structure–activity relationship between inhibitors and the ESBLs,
as well as on recent clinical outcome studies.
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CURRENT POLICY FOR
ESBL-PRODUCING
ENTEROBACTERIACEAE
Since the beginning of the 21st century, there has
been increasing concern over the optimal thera-
peutic approach for patients infected with ESBL-
producing Enterobacteriaceae [1–5]. One early
report, by Paterson et al. [1], described a prospec-
tive evaluation of ten patients with bacteraemia
caused by ESBL-positive Klebsiella pneumoniae.
Failure was deﬁned as death at 14 days or
bacteraemia persisting for ‡2 days under treat-
ment. They found that four of seven patients
whose infecting organism required an MIC
<8 mg ⁄L for the prescribed cephalosporin re-
sponded to therapy, whereas none of three
improved when the MIC was 8–16 mg ⁄L [1]. In
a review of the literature, they found 26 addi-
tional cases of K. pneumonia bacteraemia in which
the patients had been treated with a non-
carbapenem b-lactam antibiotic, with ten of 25
responding when the MIC was <8 mg ⁄L, while in
the sole case with a reported MIC of 16 mg ⁄L,
therapy failed [1]. At nearly the same time,
Lautenbach et al. [2] reported a case series of 33
patients with bacteraemia caused by ESBL-pro-
ducing K. pneumoniae and Escherichia coli whom
they matched with 66 controls. While there was
no difference between the mortality of the case
and the control patients, the case patients received
effective therapy 60 h later than the control
patients and stayed in hospital signiﬁcantly long-
er, leading to an average hospital cost in excess of
$44 000 [2]. These, along with the other subse-
quent observations [3–6], led to the CLSI recom-
mendation to report ESBL-producing E. coli and
Klebsiella spp. as resistant to all penicillin, true
cephalosporin and monobactam antimicrobials,
but as susceptible to b-lactam–b-lactamase inhib-
itor combinations provided that they tested as
such in the laboratory [7]. However, there had
been only modest experience with the b-lactam–
b-lactamase inhibitor agents, and some experts
recommend the use of a carbapenem antibiotic for
all cases of serious infection because of ESBL-
producing bacteria [1,4].
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CLINICAL EXPERIENCE WITH
b -LACTAM–b -LACTAMASE
INHIBITOR COMBINATIONS
Reports that address the role of b-lactam–b-lac-
tamase inhibitors in the treatment of infections
with ESBL-producing bacteria have appeared.
The ﬁrst of these was from Tumbarello and
co-workers [8]. They evaluated treatment out-
come in 48 cases of infection caused by ESBL-
producing bacteria, compared with 99 control
cases. The rate of failure in the patients infected
with ESBL producers was nearly twice that of the
controls (31% vs. 17%), with a 21-day mortality
rates of 52% and 29%, respectively [8]. Inade-
quate initial therapy (based on in-vitro suscepti-
bility) was 50% for the patients infected with
ESBL producers vs. 2% for those with infections
caused by ESBL-non-producing K. pneumoniae.
Inadequate treatment was seen for all 17 patients
who received a cephalosporin, ﬁve of eight who
received a ﬂuoroquinolone, and two of eight who
received a b-lactam–b-lactamase inhibitor combi-
nation [8]. Importantly, deﬁnitive therapy leading
to a successful outcome was treatment with a
carbapenem in 33% of the cases, an aminoglyco-
side in 22%, a ﬂuoroquinolone in 17%, and a
b-lactam–b-lactamase inhibitor combination in
28% [8]. This was the ﬁrst large series of patients
with ESBL-producing Enterobacteriaceae treated
with b-lactam–b-lactamase inhibitor agents, and it
demonstrated, when the in-vitro testing indicated
susceptibility, that a successful outcome could be
expected. A recent publication by Gavin et al. [9]
revealed a similar outcome. They investigated the
impact of the use of b-lactam–b-lactamase inhib-
itor agents on patients infected with ESBL-pro-
ducing strains of E. coli and Klebsiella spp. from
seven medical centres across North America. In
total, 148 patient records were reviewed, with
30% of these patients receiving a ﬂuoroquinolone,
18% a carbapenem, 16% piperacillin–tazobactam,
9% other b-lactams, 7% ampicillin–sulbactam,
6% aminoglycosides, and 6% trimethoprim–sul-
phamethoxazole [9]. Among these patients, 83%
were given monotherapy. Twenty-three patients
received piperacillin–tazobactam, and of these, 17
had infections involving sites outside the urinary
tract [9]. For infections where the organism
required an MIC of piperacillin–tazobactam of
£16 mg ⁄L (the current susceptibility breakpoint) a
successful outcome was reported in 14 of 15 cases,
including ten of 11 non-urinary tract infections.
Only one of ﬁve non-urinary tract infections
responded when the piperacillin–tazobactam
MIC exceeded 16 mg ⁄L. The authors also in-
cluded the interesting observation that merope-
nem therapy was successful in only two of four
piperacillin–tazobactam-resistant infections, dem-
onstrating that even the carbapenems are not
uniformly effective in the treatment of non-uri-
nary tract infections caused by ESBL-producing
bacteria [9]. The most recent series, described by
Rodrı´guez-Ban˜o et al. [10], analysed the outcome
of 43 episodes of E. coli bacteraemia caused by
ESBL-producing strains (primarily CTX-M-14).
Mortality was lower when patients were given a
b-lactam–b-lactamase inhibitor combination or
carbapenem, as compared with either a cephalo-
sporin or ﬂuoroquinolone (9% vs. 35%, p 0.05). In
this series, the E. coli susceptibility was 100% to
meropenem, 95% to piperacillin–tazobactam,
26% to ciproﬂoxacin and 0% to the cephalospo-
rins [10].
Many authors have reported ancillary or ecolo-
gical supporting evidence for the activity of
b-lactam–b-lactamase inhibitor combinations
against ESBL-producing bacteria, i.e., use of these
agents as a replacement for extended-spectrum
cephalosporin drugs as part of a formulary strat-
egy to lower the prevalence of ESBL-producing
Gram-negative bacilli in healthcare settings [11–
16]. The capacity to change antimicrobial agent
prescribing habits to include the use of more b-
lactam–b-lactamase inhibitor compounds that
then lead to a signiﬁcant reduction of infections
due to ESBL-producing Gram-negative bacteria
strongly suggests that these compounds have a
useful antibacterial impact on this group of resis-
tant bacteria.
LABORATORY RATIONALE AS TO
THE UTILITY OF b -LACTAM–b -
LACTAMASE INHIBITOR
COMPOUNDS
It is always useful when scientiﬁc reports support
clinical observations concerning the action of
antimicrobial compounds. Such evidence is avail-
able for the b-lactamase inhibitor drugs. The
sulphone inhibitors, tazobactam and sulbactam,
as well as clavulanate, are all small molecules
compared with the larger extended-spectrum
cephalosporins [17]. Thus, they are able to ﬁt into
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the binding pocket of both the typical
b-lactamases and the ESBL enzymes, the latter
having a structural rearrangement of amino-acid
residues leading to an altered conﬁguration of the
binding pocket that is opened to accommodate
the bulky side chain of third- and fourth-gener-
ation cephalosporin antibiotics [18]. Therefore, it
is not surprising that the inhibitor compounds
should have an impact on the traditional
b-lactamases as well as the emerging ESBL
enzymes; they are able to reach the binding
pocket in b-lactamases of both groups. An
expanded use of these inhibitor compounds
against susceptible ESBL-producing bacteria
would be a welcome addition to our dwindling
antibiotic armentarium [19].
One additional, and little appreciated, action of
the b-lactamase inhibitor agents is their effect on
accessory penicillin-binding protein targets in
both Gram-positive and Gram-negative bacteria.
They have been shown to enhance cephalosporin
action against non-b-lactamase-producing Staphy-
lococcus aureus, as well as ampicillin action against
E. coli and Proteus spp., through their capacity to
bind secondary penicillin-binding proteins, which
augments the bactericidal effect when combined
with b-lactam drugs, even in penicillin- and
ampicillin-sensitive strains [20,21].
IMPLICATIONS FOR PATIENT CARE
We live in an era of increasing resistance to
antimicrobial agents, with the emergence and
global dissemination of new resistance pheno-
types, such as ESBL-producing bacteria. Carpin
et al. [22] have demonstrated that patients can
acquire ESBL-producing bacteria from contact
with healthcare personnel and then carry them
for many years. Piperacillin–tazobactam has
retained excellent activity against E. coli and Kle-
bsiella species in general. Among strains recovered
from patients in 25 intensive care units across
North America, c. 95% of the E. coli and 90% of
the Klebsiella spp. isolates were fully susceptible
[23]. In a European collection of isolates from 14
centres, 93% of the E. coli isolates showed suscep-
tibility. However, the Klebsiella isolates showed
more resistance, with only 72% fully susceptible,
demonstrating the need to know local susceptibil-
ity patterns as well as to have reliable laboratory
testing readily available [24]. Increasing resistance
within ESBL-producing Enterobacteriaceae is a
concern that must be followed to permit clinicians
to properly select initial therapy before patient-
speciﬁc susceptibility results are reported. This is
highlighted by the newest report from Sader et al.
[25], who published their worldwide data on the
susceptibility of proven ESBL producers. They
found that for E. coli isolates with a conﬁrmed
ESBL phenotype recovered between 1998 and
2004, the susceptibility rate to piperacillin–tazo-
bactam in North America was 83%, whereas in the
remainder of the world it was 74% [25].
Laboratories must critically look for ESBL-
producing pathogens, as indicated by a recent
study by Gavin et al. [26], who found that the
majority of physicians changed therapy after a
report of an ESBL-producing pathogen from the
laboratory; 40% altered the regimen to appropri-
ate monotherapy; and another 23% substituted an
active for the initially used inactive antibiotic.
After the microbiology report was generated, 54%
of the patients were treated with piperacillin–
tazobactam, 20% with a carbapenem, and 11%
with a ﬂuoroquinolone.
CONCLUSION
Appropriate therapy for infections caused by
ESBL-producing Enterobacteriaceae is an increas-
ing global problem. Current laboratory and clinical
evidence indicates: (i) that practicing physicians
understand the implications of these infections
when they receive a report from the laboratory; (ii)
that b-lactam–b-lactamase inhibitor compounds
can be successfully used in the treatment of these
infections when the causative pathogens test as
susceptible in the laboratory and that current CLSI
guidelines are appropriate for this group of anti-
biotics; and (iii) that piperacillin–tazobactam is
clinically reliable for the treatment of serious
infection caused by susceptible strains of ESBL-
producing E. coli and Klebsiella spp.
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